Zhou W - Search Results

1

Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma.

Vo TT, Espirito JL, Boyd M, Gumuscu B, Chirovsky D, Robert NJ, Swaby RF, Zhou W, Cowey CL. Vo TT, et al. Among authors: zhou w. Future Oncol. 2022 Jun;18(17):2087-2099. doi: 10.2217/fon-2021-1229. Epub 2022 Mar 4. Future Oncol. 2022. PMID: 35240857

2

Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.

Høgdall E, Høgdall C, Vo T, Zhou W, Huang L, Marton M, Keefe SM, Busch-Sørensen M, Sørensen SM, Georgsen J, Mejlgaard E, Nedergaard L, Steiniche T. Høgdall E, et al. Among authors: zhou w. Int J Gynecol Cancer. 2020 Jul;30(7):1034-1042. doi: 10.1136/ijgc-2019-001109. Epub 2020 Jun 11. Int J Gynecol Cancer. 2020. PMID: 32527769

3

Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab.

Jemielita T, Li XN, Burke T, Liaw KL, Zhou W, Chen C. Jemielita T, et al. Among authors: zhou w. JCO Clin Cancer Inform. 2021 Aug;5:849-858. doi: 10.1200/CCI.21.00042. JCO Clin Cancer Inform. 2021. PMID: 34415774 Free article.

4

Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.

Jemielita T, Li XN, Piperdi B, Zhou W, Burke T, Chen C. Jemielita T, et al. Among authors: zhou w. JCO Clin Cancer Inform. 2021 Jan;5:56-65. doi: 10.1200/CCI.20.00099. JCO Clin Cancer Inform. 2021. PMID: 33439727 Free article. Clinical Trial.

5

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Ribas A, et al. Among authors: zhou w. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115796 Free PMC article. Clinical Trial.

6

PD-L1 expression and overall survival in Asian and western patients with gastric cancer.

Rha SY, Ku GY, Kim HS, Chung HC, Amlashi FG, Maru DM, Fein CA, Tang LH, Zhou W, Wu T, Peter SA, Kelsen DP, Ajani JA. Rha SY, et al. Among authors: zhou w. Future Oncol. 2022 Jul;18(21):2623-2634. doi: 10.2217/fon-2022-0103. Epub 2022 May 26. Future Oncol. 2022. PMID: 35616013

7

Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.

Shao C, Liu J, Zhou W, Raut MK, Monberg M, Cao X, Ricart AD, Balakumaran A. Shao C, et al. Among authors: zhou w. Leuk Lymphoma. 2019 Apr;60(4):947-954. doi: 10.1080/10428194.2018.1508665. Epub 2018 Sep 20. Leuk Lymphoma. 2019. PMID: 30234407

8

Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers.

Steiniche T, Ladekarl M, Georgsen JB, Andreasen S, Busch-Sørensen M, Zhou W, Marton MJ, Pruitt SK, Jin F, Liaw KL. Steiniche T, et al. Among authors: zhou w. Future Sci OA. 2020 Aug 19;6(8):FSO616. doi: 10.2144/fsoa-2020-0063. Future Sci OA. 2020. PMID: 32983568 Free PMC article.

9

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Petrella TM, Robert C, Richtig E, Miller WH Jr, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J. Petrella TM, et al. Among authors: zhou w. Eur J Cancer. 2017 Nov;86:115-124. doi: 10.1016/j.ejca.2017.08.032. Epub 2017 Oct 4. Eur J Cancer. 2017. PMID: 28987768 Free article. Clinical Trial.

10

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer.

Cho JH, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski MA, Kim J. Cho JH, et al. Among authors: zhou w. Cancer Res Treat. 2018 Jan;50(1):95-102. doi: 10.4143/crt.2016.591. Epub 2017 Mar 17. Cancer Res Treat. 2018. PMID: 28301925 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21,323 results

Search Page